Crossmark

Targeting cardiac myosin in HFrEF: mechanism, clinical evidence, and the role of omecamtiv mecarbil

Crossref DOI link: https://doi.org/10.1186/s13019-026-04427-9

Published Online: 2026-06-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abady, Eslam https://orcid.org/0009-0007-2087-3297
Elewa, Mandy https://orcid.org/0000-0001-9750-4413
Karam, Karrar Naem https://orcid.org/0009-0003-8676-7367
Mathew, Kevin Thomas https://orcid.org/0009-0009-8278-6994
Bedair, Mahmoud https://orcid.org/0009-0007-8735-9073
Almashaqbeh, Suleiman N. https://orcid.org/0009-0004-1647-1461
Alwarraqi, Asmaa G. https://orcid.org/0000-0003-1690-5878
AbuEl-Enien, Hazem https://orcid.org/0000-0002-9356-0554
Samadi, Yahya https://orcid.org/0009-0005-4872-5603
Abouelmad, Khaled https://orcid.org/0000-0003-3919-9873
License Information

Text and Data Mining valid from 2026-06-14

Accepted Manuscript valid from 2026-06-14
More Information

Article History

Received: 4 April 2026

Accepted: 9 June 2026

First Online: 14 June 2026

Declarations

:

: Not applicable.

: All authors have approved the manuscript and agree with its submission to the journal.

: The authors declare no competing interests.